Find your next paid study

University of Colorado, DenverNCT06559189

Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP…

Leukemia, Myeloid, Acute

Delta-Fly Pharma, Inc.NCT06382168

~$10 – $8,750

Phase 2

Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell Transplant

The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug c…

GVHD,AcuteAcute LeukemiaMyelodysplastic Syndromes+1 more

University of Alabama at BirminghamNCT06315309

Observational

Nutrition and Exercise to Optimize Muscle and Adiposity in Adults With ALL: NEOMA ALL Trial

This clinical trial aims to assess the effect of nutrition and exercise on muscle and adiposity in adults with Philadelphia Chromosome (Ph) Negative B-ALL unde…

Philadelphia Chromosome NegativeB Cell Acute Lymphoblastic Leukemia (B-ALL)B-ALL

University of ChicagoNCT06785324

Registry for Adults With Plasma Cell Disorders (PCD's)

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (…

Multiple MyelomaAmyloidosisCryoglobulinemia+6 more

UNC Lineberger Comprehensive Cancer CenterNCT03717844

~$10 – $750

Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or re…

~$10 – $8,750

Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaHigh-risk Myelodysplastic Syndrome

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of …

Vincerx Pharma, Inc.NCT06034275

~$10 – $8,750

Observational

Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial

This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared t…

LeukemiaMyelomaMyelodysplastic Syndromes+3 more

Dana-Farber Cancer InstituteNCT06487247

~$10 – $7,500

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more

Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) Inhibition

This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with s…

Fox Chase Cancer CenterNCT06218628

Phase 2

ABBA CORD: Double Umbilical Cord Blood Transplants With Abatacept for Graft Versus Host Disease Prophylaxis

The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is…

Acute Myelogenous LeukemiaAcute Lymphatic LeukemiaChronic Myelogenous Leukemia+5 more

Leland MethenyNCT06680661

~$10 – $7,500

Acute Myeloid Leukemia With FLT3/ITD Mutation

A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia

This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given …

H. Lee Moffitt Cancer Center and Research InstituteNCT05024552

Acute Myeloid Leukemia (AML) in Remission

Phase IB/II of CPX-351 as Maintenance Therapy in AML Patients Ineligible for Bone Marrow Transplantation

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as…